Stock Comparison

INCY vs LLY

Incyte Corp vs Eli Lilly and Co

The Verdict

INCY takes this one.

Winner

INCY

Incyte Corp

0.6

out of 10

Distressed

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$20.8B

Market Cap

$965.0B

14.5

P/E Ratio

52.6

26.7%

Profit Margin

N/A

29.2%

Return on Equity

N/A

0.0

Debt-to-Equity

N/A

Moderate

Overall Risk

Moderate

0.6

DVR Score

0.5

The Deep Dive

INCY0.6/10

Incyte (INCY) is a well-established large-cap biopharmaceutical company ($20.45B market cap) showing solid Q1 2026 performance with an 85.4% YoY EPS beat and positive pipeline updates for zilurgisertib and Opzelura. These factors suggest continued steady growth and operational strength. However, consistent with previous analysis, its current size and operational maturity in the biopharmaceutical s...

Full INCY Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.